Valneva SE, the France-based vaccine company, has raised $102 million in a global share offering to specialised investors which included an offering of American Depositary Shares (ADSs) in the US and a private share placement in Europe and elsewhere. The proceeds are expected to be used for the company’s vaccine portfolio which includes a candidate Covid-19 vaccine. Valneva’s ordinary shares are listed on Euronext Paris, and its ADSs trade on Nasdaq.
